Aligos Therapeutics’ (ALGS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $70.00 price objective on the stock.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $8.25 on Monday. Aligos Therapeutics has a 1 year low of $6.76 and a 1 year high of $46.80. The company’s 50 day simple moving average is $18.69 and its 200 day simple moving average is $20.25. The company has a market capitalization of $50.44 million, a price-to-earnings ratio of -0.62 and a beta of 2.52.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Monday, March 10th. The company reported ($13.08) EPS for the quarter, missing analysts’ consensus estimates of ($2.63) by ($10.45). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The business had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $0.43 million. During the same period in the prior year, the firm earned ($5.50) EPS. Equities analysts expect that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Drive Wealth Management LLC acquired a new position in shares of Aligos Therapeutics in the 4th quarter valued at about $916,000. Avantax Advisory Services Inc. purchased a new position in Aligos Therapeutics in the fourth quarter valued at approximately $1,218,000. Golden State Wealth Management LLC acquired a new position in Aligos Therapeutics during the fourth quarter valued at approximately $107,000. AlphaMark Advisors LLC grew its stake in Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after buying an additional 1,000 shares during the period. Finally, Northern Trust Corp acquired a new stake in shares of Aligos Therapeutics in the fourth quarter worth $205,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).